Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.
The post Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition appeared first on MedCity News.
